title: Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease.
abstract: OBJECTIVE
  Patients with Alzheimer's disease (AD) and cerebrovascular disease (CVD) show greater attentional deficits compared with AD patients without CVD. The aim of the present study was to investigate the effect of galantamine on attention in AD patients with CVD.
  
  
  METHODS
  In this open trial, 1512 patients with AD and CVD were recruited from 71 nationwide hospitals. The patients were given galantamine for 16 weeks. The primary outcome measure was the score on the Attention Questionnaire Scale (AQS), which measures the patients' attention in their daily lives. The secondary outcome measures were the scores on the Korean Mini-Mental State Examination, the Clinical Dementia Rating scale and the Global Deterioration Scale. Efficacy measures were calculated both at baseline and at the end of the treatment (week 16).
  
  
  RESULTS
  The responders rate on the AQS (change of the AQS from baseline >0) was 60.6% in AD patients with CVD. At the end of the treatment, both the AQS (15.0 ± 5.7 vs 16.3 ± 5.8, P < 0.001) and the Korean Mini-Mental State Examination scores (17.8 ± 4.8 vs 18.1 ± 5.1, P < 0.001) showed a significant improvement relative to the baseline performance. The Clinical Dementia Rating (1.25 ± 0.59 vs 1.22 ± 0.63 P = 0.025) and Global Deterioration Scale (3.82 ± 0.94 vs 3.76 ± 0.96, P = 0.002) scores also showed a significant decrease at the end of the treatment.
  
  
  CONCLUSIONS
  Galantamine is effective in improving attention in the daily lives of AD patients with CVD. Geriatr Gerontol Int 2017; 17: 1661-1668.
authors.affiliation: Department of Neurology, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea.
authors.forename: Jeong Jin
authors.initials: JJ
authors.lastname: Park
authors.affiliation: Department of Neurology, Inha University School of Medicine, Incheon, Korea.
authors.forename: Seong Hye
authors.initials: SH
authors.lastname: Choi
authors.affiliation: Department of Neurology, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: SangYun
authors.initials: S
authors.lastname: Kim
authors.affiliation: Department of Neurology, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Ae Young
authors.initials: AY
authors.lastname: Lee
authors.affiliation: Department of Neurology, Ajou University School of Medicine, Suwon, Korea.
authors.forename: So Young
authors.initials: SY
authors.lastname: Moon
authors.affiliation: Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.
authors.forename: Jun Hong
authors.initials: JH
authors.lastname: Lee
authors.affiliation: Department of Neurology, Changwon Fatima Hospital, Changwon, Korea.
authors.forename: Jae Cheol
authors.initials: JC
authors.lastname: Kwon
authors.affiliation: Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.
authors.forename: Kyung Won
authors.initials: KW
authors.lastname: Park
authors.affiliation: Department of Neurology, International St. Mary's Hospital, College of Medicine, Catholic Kwandong University, Incheon, Korea.
authors.forename: Bon D
authors.initials: BD
authors.lastname: Ku
authors.affiliation: Department of Neurology, Myongji Hospital, Seonam University College of Medicine, Goyang, Korea.
authors.forename: Hyun Jeong
authors.initials: HJ
authors.lastname: Han
authors.affiliation: Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea.
authors.forename: Eun-Joo
authors.initials: EJ
authors.lastname: Kim
authors.affiliation: Department of Neurology, The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea.
authors.forename: Yong S
authors.initials: YS
authors.lastname: Shim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D001288:Attention / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000523:psychology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D005260:Female; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D005702:Galantamine
keywords: Alzheimer's disease; attention; cerebrovascular disease; dementia; galantamine